Tests UBT251 in adults living with overweight or obesity
Tests UBT251 against a placebo in adults living with overweight or obesity.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Cypress and Overland Park, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- NCT07395687
- U1111-1324-3831
- Registry title
- A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 333 people, planned
- Started
- 2 Feb 2026
- Expected to end
- 18 Feb 2027
- Type of study
- Interventional, 11 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- UBT251
- Placebo
- Record updated
- 21 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living with overweight or obesity to test how safe and effective UBT251 is compared with placebo.
- Age
- 18 to 65 years. Part A: 18-55 years. Part B: 18-65 years. Part C: 18-55 years.
- Sex
- Men and women (sex at birth).
- Disease stage
- Overweight or obesity due to excess fat tissue. BMI Part A: 27.0-39.9 kg/m^2. Part B: 30.0-50.0 kg/m^2. Part C: 24-34.9 kg/m^2.
- Earlier treatment
- Must not have used any marketed GLP-1, GIP or glucagon receptor agonist medicine within 90 days before screening.
Main reasons for not taking part
- Known or suspected allergy to the study medicine or related products
- Treatment with a marketed GLP-1, GIP or glucagon receptor agonist medicine within 90 days before screening
- Any condition that, in the investigator's opinion, could risk safety or following the study plan
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or female (sex at birth)
- For Part C: Japanese, Chinese or non-Asian participants (all self-reported):; For Japanese participants: both parents of Japanese descent; For Chinese participants: both parents of Chinese descent; For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia)
- Age at the time of signing the informed consent:; For Part A: 18-55 years (both inclusive); For Part B: 18-65 years (both inclusive); For Part C: 18-55 years (both inclusive)
- BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):; For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive); For Part B: 30.0-50.0 kg/m\^2 (both inclusive); For Part C: 24-34.9 kg/m\^2 (both inclusive)
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator
Who cannot take part
- Known or suspected hypersensitivity to study intervention(s) or related products
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
Also in 1 other country, 1 site
- Altasciences Clinical LA, Inc.Cypress, United StatesContact: Novo NordiskTaking people
- Altasciences Clinical Kansas, Inc.Overland Park, United StatesContact: Novo NordiskTaking people
About the trial
What the trial wants to find out
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
The 11 groups in the trial
- Part A - UBT251Treatment being tested
Participants will be randomized to receive multiple dose levels subcutaneously.
Treatment: UBT251
- Part A - placeboPlacebo, for comparison
Participants will receive placebo matched to UBT251 subcutaneously.
Treatment: Placebo
- Part B - Arm A (UBT251)Treatment being tested
Participants will be randomized to receive multiple dose levels subcutaneously.
Treatment: UBT251
- Part B - Arm B (UBT251)Treatment being tested
Participants will be randomized to receive multiple dose levels subcutaneously.
Treatment: UBT251
- Part B - Arm C (UBT251)Treatment being tested
Participants will be randomized to receive multiple dose levels subcutaneously.
Treatment: UBT251
- Part B - Arm D (UBT251)Treatment being tested
Participants will be randomized to receive 2 dose levels subcutaneously.
Treatment: UBT251
- Part B - Arm E (UBT251)Treatment being tested
Participants will be randomized to receive a single dose level subcutaneously.
Treatment: UBT251
- Part B - placeboPlacebo, for comparison
Participants will receive placebo matching one of the UBT251 arms subcutaneously.
Treatment: Placebo
- Part C - UBT251 dose 1Treatment being tested
Participants will be randomized to receive dose level 1 subcutaneously.
Treatment: UBT251
- Part C - UBT251 dose 2Treatment being tested
Participants will be randomized to receive dose level 2 subcutaneously.
Treatment: UBT251
- Part C - UBT251 dose 3Treatment being tested
Participants will be randomized to receive dose level 3 subcutaneously.
Treatment: UBT251
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
- Plain-language title
- Tests UBT251 in adults living with overweight or obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07395687, who can take part
- Record updated
- 21 April 2026